Table 3. Analysis of event risk between the four groups according to AoAC severity and LVH type.
| Events | Crude | Model 1＊ | Model 2＊＊ | Model 3＊＊＊ | Model 4＊＊＊＊ | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| CV mortality | ||||||||||
| Non-to-mild AoAC with eccentric LVH | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – |
| Non-to-mild AoAC with concentric LVH | 1.54 (0.62–3.86) | 0.36 | 1.71 (0.68–4.31) | 0.25 | 1.49 (0.58–3.85) | 0.41 | 1.47 (0.57–3.82) | 0.43 | 1.44 (0.56–3.71) | 0.45 |
| Moderate-to-severe AoAC with eccentric LVH | 1.23 (0.45–3.39) | 0.69 | 1.14 (0.41–3.17) | 0.81 | 1.16 (0.41–3.26) | 0.78 | 1.16 (0.41–3.27) | 0.78 | 1.19 (0.43–3.33) | 0.73 |
| Moderate-to-severe AoAC with concentric LVH | 5.01 (2.38–10.52) | 0.002 | 4.07 (1.68–9.84) | 0.002 | 3.68 (1.48–9.17) | 0.01 | 3.68 (1.47–9.18) | 0.005 | 4.08 (1.64–10.13) | 0.002 |
| Mortality | ||||||||||
| Non-to-mild AoAC with eccentric LVH | 1 | – | 1 | – | 1 | – | 1 | – | 1 | – |
| Non-to-mild AoAC with concentric LVH | 1.38 (0.60–3.15) | 0.45 | 1.56 (0.68–3.57) | 0.29 | 1.28 (0.54–3.01) | 0.58 | 1.26 (0.53–2.99) | 0.60 | 1.21 (0.51–2.83) | 0.67 |
| Moderate-to-severe AoAC with eccentric LVH | 1.43 (0.60–3.40) | 0.41 | 1.25 (0.52–2.99) | 0.62 | 1.12 (0.45–2.76) | 0.81 | 1.11 (0.45–2.75) | 0.82 | 1.21 (0.49–2.95) | 0.68 |
| Moderate-to-severe AoAC with concentric LVH | 3.35 (1.57–7.15) | 0.002 | 3.22 (1.46–7.10) | 0.004 | 2.78 (1.22–6.33) | 0.02 | 2.77 (1.21–6.31) | 0.02 | 3.31 (1.46–7.49) | 0.004 |
＊Adjusted for age and sex
＊＊Adjusted for age, sex, peripheral artery disease, and albumin
＊＊＊ Adjusted for age, sex, peripheral artery disease, albumin, and dialysis vintage
＊＊＊＊ Adjusted for age, sex, peripheral artery disease, albumin, dialysis vintage, and ESKD cause.
AoAC, aortic arch calcification; CI, confidence interval; CV, cardiovascular; ESKD, end-stage kidney disease; HR, hazard ratio; LVH, left ventricular hypertrophy